Search Medical Condition
Please enter condition
Please choose location from dropdown

Chandigarh, India Clinical Trials

A listing of Chandigarh, India clinical trials actively recruiting patients volunteers.

RESULTS

Found (69) clinical trials

Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas

AIMS AND OBJECTIVES: To compare the effectiveness and safety of oral atenolol versus oral propranolol in the treatment of infantile hemangiomas. To elucidate the mechanism of action of atenolol and propranolol in the treatment of infantile hemangiomas. STUDY DESIGN MATERIALS AND METHODS: This investigator-initiated, prospective, observer blinded, parallel group comparative ...

Phase

2.41 miles

Learn More »

G-CSF in Decompensated Cirrhosis: an Open Label Trial

Globally, cirrhosis is the fifth commonest cause of mortality. Its natural history is typified by an initial, largely asymptomatic, "compensated" phase followed by "decompensation" due to complications of raised portal pressures and hepatocellular dysfunction. Currently the only definitive treatment option for cirrhosis is liver transplantation which is limited in its ...

Phase

2.41 miles

Learn More »

7-days Versus 14 Days of Antibiotics Therapy for Ventilator Associated Pneumonia

Ventilator-associated pneumonia (VAP) is one of the major causes of morbidity and mortality in the ICU, accounting for 25% of the total infections occurring in this setting and 50% of all antibiotic prescriptions in patients who are mechanically ventilated.1,2 The incidence of VAP depends not only on the type of ...

Phase N/A

2.41 miles

Learn More »

DAA Therapy in Pediatric Patients With Chronic Hepatitis C

Consecutive chronic hepatitis C (HCV) infected children [age: 12 to <18 years; both treatment-nave (TN) and treatment-experienced, (TE)] are being enrolled. Genotyping is not recommended for non-cirrhotic or TN patients and were treated with SOF+DCV for 12-weeks, while genotyping is recommended for patients with cirrhosis and TE patients. Patients with ...

Phase N/A

2.41 miles

Learn More »

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Subjects will be randomised in a 1:1 ratio to receive either SB11 or Lucentis (administered via intravitreal (ITV) 0.5 mg every 4 weeks). Investigational Products (IP) (SB11 or Lucentis) will be administered up to Week 48, and the last assessment will be done at Week 52.

Phase

2.41 miles

Learn More »

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

An algorithm was developed using SOF-based regimens to treat all patients (RKD). Genotyping is not recommended for patients without cirrhosis of liver and they are being treated with SOF+DCV for 12-weeks, while genotyping is recommended for patients with cirrhosis of liver (Figure 1). Patients with liver cirrhosis and genotype 3 ...

Phase N/A

2.41 miles

Learn More »

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

This study is a randomized, double-blind, placebo-controlled, 72-week study followed by a 72-week open-label period. The purpose is to characterize the long-term effects of ataluren-mediated dystrophin restoration on disease progression. Participants will be randomized in a 1:1 ratio to ataluren or placebo. Participants will receive blinded study drug three times ...

Phase

2.41 miles

Learn More »

Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"

Very recently, pioglitazone was banned for use in type 2 diabetes patients in India as well, by the notification from Government of India based on a case series - the ban was revoked a few days later due to lack of evidence. The incidence rates of bladder cancer among different ...

Phase N/A

2.41 miles

Learn More »

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

The systemic vasculitides are a group of uncommon but important diseases whose prognosis has improved dramatically with the use of immunosuppressive therapy. However, long-term morbidity from recurrent disease flares, low-grade grumbling disease and/or accumulating damage from previous disease activity or drug therapy now characterise the long-term outlook for patients with ...

Phase N/A

2.41 miles

Learn More »

Incretin Axis in Type 1 Diabetes Mellitus

Glucose is the most important physiologic substance involved in the regulation of insulin release. The effect of glucose on the beta cell is dose related. Dose-dependent increases in concentrations of insulin and C-peptide and in rates of insulin secretion have been observed after oral and intravenous glucose loads with 1.4 ...

Phase N/A

2.41 miles

Learn More »